AiVita Biomedical
Irvine, US · Founded 2016 · Delaware corporation · 1 known investors
Find your way into AiVita Biomedical
53 people in our graph share verified history with the AiVita Biomedical team — schools, employers, funds. One of them is your warm intro.
Ryan Laurinunlockedknows Gabriel Nistor · together at UC Irvine (overlapped)
×10knows the team · via UC Irvine
knows the team · via AIVITA Biomedical Inc
AIVITA Biomedical is a biotechnology company developing personalized vaccines using an autologous cell therapy platform, including a pan-antigenic cancer vaccine that targets all neoantigens and a multi-pathogen vaccine kit for infectious disease prevention. Its work draws on expertise in stem cell growth and high-purity cell differentiation.
Founders & leadership
AiVita Biomedical was founded in 2016 by Hans S. Keirstead.
HS
Hans S. KeirsteadFounder
GN
Gabriel NistorinExecutiveGabriel Nistor has expertise in translating scientific discoveries into therapeutic applications, with a background in clinical protocol development, regulatory affairs, and immunology-focused areas including immuno-oncology and vaccine development. He has led cross-functional teams including clinicians and regulatory specialists in advancing medical treatments and vaccines toward clinical approval.
EI
Ed InalExecutive
Board
AB
Alexander B. SuhBoard director
SB
Susan BloomfieldBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$39.5M disclosed across 4 rounds · 2016–2022
▶$6MraisedAug 2022 · 4 investors · BiotechnologyRule 506(b)
▶$6MraisedAug 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chris FibigerDirector
- Scott BurellExecutive Officer
- Ungbae LeeDirector
- Paul JenkinsonDirector
- Matthew KatzDirector
- Philippe SchaisonDirector
- Hans KeirsteadExecutive Officer, Director
- Alexander SuhDirector
- Offering amount
- $85M
- Amount sold
- $6M
- Minimum investment
- $250K
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11MraisedDec 2019 · 2 investors · BiotechnologyRule 506(b)
▶$11MraisedDec 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew KatzDirector
- Hans KeirsteadExecutive Officer, Director
- Scott BurellExecutive Officer
- Alexander SuhDirector
- Ungbae LeeDirector
- Paul JenkinsonDirector
- Philippe SchaisonDirector
- Offering amount
- $25M
- Amount sold
- $11M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$17MraisedJul 2018 · 8 investors · BiotechnologyRule 506(b)
▶$17MraisedJul 2018 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gabriel NistorExecutive Officer
- Alexander B. SuhDirector
- Hans S. KeirsteadExecutive Officer, Director
- Susan BloomfieldDirector
- Ungbae LeeDirector
- Ed InalExecutive Officer
- Offering amount
- $17M
- Amount sold
- $17M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$5.5MraisedMar 2018 · 20 investors · BiotechnologyRule 506(b)
▶$5.5MraisedMar 2018 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hans S. KeirsteadExecutive Officer, Director
- Alexander B. SuhDirector
- Gabriel NistorExecutive Officer
- Susan BloomfieldDirector
- Ed InalExecutive Officer
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Avita Medical28 shared keywordsRECELL is an FDA-approved autologous skin cell suspension device for treating burns, trauma, and surgical wounds by harvesting a patient's own skin cells and applying them to accelerate healing and reduce the need for large skin grafts. The technology serves hospital systems and wound care clinicians treating severe burn and trauma patients.
Ideaya Biosciences11 shared keywordsIDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers. Its lead candidate, darovasertib, is in late-stage trials for uveal melanoma, with a pipeline spanning PKC inhibition, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition.
Globaldata10 shared keywordsGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
Companies competing with AiVita Biomedical for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does AiVita Biomedical do?
- AIVITA Biomedical is a biotechnology company developing personalized vaccines using an autologous cell therapy platform, including a pan-antigenic cancer vaccine that targets all neoantigens and a multi-pathogen vaccine kit for infectious disease prevention. Its work draws on expertise in stem cell growth and high-purity cell differentiation.
- Who founded AiVita Biomedical?
- AiVita Biomedical was founded by Hans S. Keirstead in 2016.
- Who are AiVita Biomedical's investors?
- AiVita Biomedical's investors include JLS.
- How much funding has AiVita Biomedical raised?
- AiVita Biomedical has disclosed $39.5M raised across 4 rounds.
- Where is AiVita Biomedical headquartered?
- AiVita Biomedical is headquartered in Irvine, US.